Blog
    Regulatory UpdateFor PhysiciansJune 30, 2026

    Peptide FDA Regulatory Status and Safety Signals

    Review FDA Category 2 status for BPC-157 and TB-500, plus safety signals for Semaglutide including gastrointestinal events and NAION reports.

    Clinical Question

    What are the current FDA regulatory statuses, compounding eligibility classifications, and documented safety signals for common peptide therapies as of early 2026?

    Evidence Snapshot

    • Regulatory Classifications: Multiple peptides (BPC-157, TB-500, CJC-1295, Ipamorelin) are currently listed as Category 2 substances by the FDA, indicating significant safety risks or lack of safety data.
    • Safety Signals: FAERS data for Semaglutide shows strong signals for gastrointestinal events (nausea, vomiting, delayed gastric emptying) and emerging signals for NAION and pulmonary aspiration.
    • Warning Letters: Regulatory actions have been issued to entities such as Tailor Made Compounding and Predator Nutrition regarding several non-FDA-approved peptides.
    • Clinical Outcomes: Phase III trial data for GLP-1 and GIP/GLP-1 agonists show significant weight loss (14.9% to 22.5%) and MACE reduction (20%).

    What the Research Shows

    Evidence regarding peptide therapy is divided between highly regulated, FDA-approved metabolic peptides and non-approved substances currently subject to regulatory restriction.

    Regulatory Status of Compounded Peptides As of March 2026, the FDA has placed several peptides into Category 2 under section 503A, which identifies substances with significant safety risks that are ineligible for routine compounding. BPC-157 is classified as Category 2 due to immunogenicity concerns and a lack of human safety data. It is not FDA-approved and was the subject of warning letters to Tailor Made Compounding and Predator Nutrition in 2020. Similarly, TB-500 is a Category 2 substance with cited immunogenicity risks and no human exposure data.

    Other peptides have seen shifts in their nomination status. CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax were all moved to Category 2 in September 2023, with subsequent nomination withdrawals or removals occurring in September 2024. The FDA specifically cited safety issues such as increased heart rate for CJC-1295. Thymosin Alpha-1, although approved in over 35 countries as Zadaxin, is not FDA-approved and was removed from Category 2 pending advisory review in September 2024, yet it remains a substance of concern under interim policy.

    Safety Signals and Clinical Trials For FDA-approved peptides like Semaglutide, postmarketing surveillance via FAERS has identified over 187,000 adverse event reports through 2023. Strong signals exist for nausea, vomiting, and delayed gastric emptying. Moderate signals have been detected for acute pancreatitis and cholelithiasis/cholecystitis. Emerging signals under evaluation include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, and pulmonary aspiration risks during general anesthesia.

    Clinical trials have established efficacy for several peptides. The STEP 1 trial (NCT03548935) demonstrated 14.9% weight loss with Semaglutide, while the SELECT trial (NCT03574597) showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial (NCT04184622). Conversely, trials for non-approved indications, such as Thymosin Alpha-1 for sepsis (NCT02867267), have shown negative results for mortality reduction.

    Mechanism

    Mechanistic data for these substances is constrained to clinical observations and regulatory citations.

    • GLP-1 Agonists (Semaglutide): Mechanism involves delayed gastric emptying, which contributes to gastrointestinal signals and potential impacts on the absorption of oral medications.
    • Growth Hormone Secretagogues (CJC-1295): Associated with increased heart rate.
    • Immunomodulators (Thymosin Alpha-1, BPC-157, GHK-Cu, GHRP-2): Regulatory bodies cite immunogenicity risk as a primary concern for these agents when compounded.

    Limitations of the Evidence

    A significant gap exists between animal or mechanistic data and human safety profiles for many peptides. BPC-157 and TB-500 specifically lack human exposure data according to FDA records. For emerging safety signals like NAION in Semaglutide users, the data is currently under EMA review (January 2025) and has not reached a definitive causal conclusion. Furthermore, many peptides approved in other jurisdictions, such as Selank and Semax (Russia) or Thymosin Alpha-1 (Zadaxin), have not met FDA safety and efficacy requirements for approval in the United States.

    Clinical Takeaway

    Physicians should note that many peptides previously available via compounding (BPC-157, CJC-1295, TB-500) are currently classified by the FDA as Category 2 substances due to immunogenicity and safety risks, making them ineligible for routine compounding. For approved therapies like Semaglutide, clinicians must monitor for established GI risks and emerging signals related to pulmonary aspiration and NAION.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2).
    • FAERS Safety Signal Database (Semaglutide).
    • Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidethymosin alpha 1cjc 1295tb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.